Skip to content
OpenCapital
Get started

EXOZ EXOZ Grant — Research And Development Costs

Similar metrics at other companies

Dianthus Therapeutics logo
DNTHOther Costs — Research And Development Expense
$1.49M+25.5%
DBV Technologies logo
DBVTExpenses by function — Research and development expense
$8.5M+84.8%
Disc Medicine logo
IRONOther Research — Research And Development Expense
$2.17M+18.2%
Nurix Therapeutics, Inc. logo
NRIXInternal research and development expenses — R&D
$57.07M+12.2%
Kopin logo
KOPNResearch And Development Funded
$3.81M+496%
Aquestive Therapeutics, Inc. logo
AQSTOther — R&D
$319K-41.6%

Other financials

Income statement

See full
Revenue$17.5K—
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation

See full
Market cap$76.8M-3.3%
Enterprise value$76.57M+3.5%
P/S1,096.1×—

Profitability

See full
Operating margin-14,489.6%—
Net margin-2,909.1%—
FCF margin-10,117.8%—

Returns & leverage

See full
Return on equity-185.8%—
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept EXOZ:ResearchAndDevelopmentCosts.

The official record: EXOZ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's grant — research and development costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EXOZ's grant — research and development costs?
EXOZ (EXOZ) reported grant — research and development costs of $1.46M in Q1 2026.
How has EXOZ's grant — research and development costs changed year-over-year?
EXOZ's grant — research and development costs increased by 27.0% year-over-year, from $1.15M to $1.46M.
What does grant — research and development costs mean?
This metric represents the total operating expenses specifically allocated to research and development activities within the grant-funded segment. It captures the investment in scientific innovation, process optimization, and technical feasibility studies required to advance proprietary biomanufacturing platforms. Monitoring this spend helps investors assess the company's commitment to technological maturation and the intensity of its innovation pipeline.